Poulos Christine, Soliman Ahmed M, Tekin Sibel, Agarwal Sanjay K
Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA.
Health Economics and Outcomes Research (HEOR), AbbVie Inc, North Chicago, IL, USA.
Expert Rev Pharmacoecon Outcomes Res. 2021 Oct;21(5):1091-1099. doi: 10.1080/14737167.2021.1832468. Epub 2020 Nov 3.
We evaluated elagolix and leuprolide from the patient's perspective for the treatment of endometriosis-related pain.
Preference weights from a published discrete choice experiment were used to evaluate preferences for treatment profiles simulating elagolix (150 mg/day and 200 mg/twice-daily dosages) and leuprolide for the treatment of moderate to severe endometriosis-related pain. Sensitivity analyses were conducted by varying the range of risk for pregnancy-related problems, moderate to severe hot flashes, and bone fracture across scenarios.
The 200 mg twice daily dosage of elagolix is more likely to be preferred over leuprolide by patients with moderate to severe endometriosis-related pain in all scenarios explored in the evaluation and sensitivity analyses. The probability that an average respondent would select a treatment was sensitive to increases in risk of moderate to severe hot flashes for leuprolide and possible variations in the risk of pregnancy-related problems for both treatments but was not influenced by an increased risk of bone fracture.
Patients' preferences for treatment of endometriosis-related pain should be evaluated using the benefits and risks of each pharmacological option. Respondents were more likely to prefer the treatment profile similar to 200 mg twice daily elagolix over that of leuprolide in all scenarios.
我们从患者角度评估了艾拉戈利克和亮丙瑞林治疗子宫内膜异位症相关疼痛的效果。
利用已发表的离散选择实验中的偏好权重，评估模拟艾拉戈利克（每日150毫克和每日两次200毫克剂量）和亮丙瑞林治疗中度至重度子宫内膜异位症相关疼痛的治疗方案偏好。通过在不同情景中改变与妊娠相关问题、中度至重度潮热和骨折的风险范围进行敏感性分析。
在评估和敏感性分析所探讨的所有情景中，对于患有中度至重度子宫内膜异位症相关疼痛的患者，艾拉戈利克每日两次200毫克的剂量比亮丙瑞林更有可能受到青睐。对于亮丙瑞林，中度至重度潮热风险的增加以及两种治疗方法中与妊娠相关问题风险的可能变化，会使普通受访者选择一种治疗方法的概率变得敏感，但不受骨折风险增加的影响。
应使用每种药物治疗方案的益处和风险来评估患者对子宫内膜异位症相关疼痛治疗的偏好。在所有情景中，受访者更倾向于选择类似于艾拉戈利克每日两次200毫克的治疗方案，而非亮丙瑞林的治疗方案。
